Summit Therapeutics Inc.
A clinical-stage biopharmaceutical company founded in 2003 in Oxford, England, that develops new medicines for serious diseases — starting with antibiotics and later shifting its focus to cancer treatments such as the lung-cancer drug ivonescimab. It went through a string of odd early names, including CobraDragon and Vastox, before settling on "Summit," a nod to reaching the peak of healthcare. Today it is listed on Nasdaq and runs offices in Miami, California, and the UK.
Sponsored American Depositary Shares (ADS)
Granted 17.65M · Bought 501.05M
Granted 14.37M · Bought 27.92M
Bought 32.06M
Bought 6.20M
Granted 97.4K · Bought 3.03M
Bought 354.4K
Granted 48.7K
Granted 44.1K
Granted 73.7K · Sold 73.7K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Duggan Robert WCo-Chief Executive Officer, Director, 10% owner · 16 transactions | — | 1.76B | 17.65M | 501.05M | — |
| Zanganeh MahkamCo-Chief Executive Officer, Director, 10% owner · 21 transactions | — | 610.02M | 14.37M | 27.92M | — |
| Xia YuDirector · 3 transactions | — | 32.06M | — | 32.06M | — |
| Zanganeh MakyCo-CEO & President, Director · 4 transactions | — | 10.56Mas of Aug 2022 | — | 6.20M | — |
| Soni Manmeet SinghCOO and CFO, Director · 5 transactions | — | 3.10M | 97.4K | 3.03M | — |
| Dhingra AnkurChief Financial Officer · 6 transactions | — | 355.0Kas of Mar 2024 | — | 354.4K | — |
| Anand BhaskarChief Accounting Officer · 2 transactions | — | 159.8K | 48.7K | — | — |
| Huber JeffDirector · 1 transaction | — | 56.1Kas of Sep 2024 | 44.1K | — | — |
| Powell David JonathanChief Scientific Officer · 11 transactions | — | 0as of Nov 2020 | 73.7K | — | 73.7K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: +570.53M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.